Company performance
Current Price
as of Jan 21, 2025$0.57
P/E Ratio
N/A
Market Cap
$166.21M
Loading...
Description
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Metrics
Overview
- HQSouth San Francisco, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerLYEL
- Price$0.5689-1.15%
Trading Information
- Market cap$166.21M
- Float51.62%
- Average Daily Volume (1m)823,721
- Average Daily Volume (3m)1,582,405
- EPS-$0.80
Company
- Revenue$0.06M
- Rev growth (1yr)36.00%
- Net income-$44.58M
- Gross margin-13,664.71%
- EBITDA margin-137,044.12%
- EBITDA-$46.60M
- EV-$28.27M
- EV/Revenue-448.66
- P/EN/A
- P/S2,314.51
- P/B0.28
Documents
SEC Filings
Factset Street Account